ClinicalTrials.gg

Program

givinostat hydrochloride

Also written as “Givinostat Hydrochloride” and “Givinostat Hydrochloride - Cohort 2”.

Its studies are mostly in Muscular Dystrophy, Duchenne, led by Italfarmaco.

Furthest: phase 2, since Dec 11, 20241 company-led study, 1 open or runningNext primary completion: Dec 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Italfarmaco11 open or runningphase 2since Dec 11, 2024Dec 11, 2024Dec 2029phase 2 · NCT06769633

Also a collaborator on its studies: Fortrea.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 11, 2024First study: phase 2 study in Muscular Dystrophy, DuchenneFirst studyNCT06769633 · 18 planned · Belgium, Italy, Netherlands and more

Ahead

  1. Dec 2029Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT06769633

TargetBeta

“Histone deacetylase inhibitor”ChEMBL 37, by rule

Other programs on the same 11 targets

ProgramCompanyFurthest phaseStudies
givinostatruleItalfarmacophase 323

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06769633Muscular Dystrophy, Duchenne · Belgium, Italy, Netherlands and more2RecruitingDec 202918

How it is read

Names in the registry

  • “Givinostat Hydrochloride”, 1 entry
  • “Givinostat Hydrochloride - Cohort 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.